

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.- 44. (Cancelled).

45. (Previously presented) A substantially pure histidine-rich glycoprotein polypeptide coupled to a detectable marker, wherein said detectable marker is a fluorescent marker, a chemiluminescent marker, an enzymatic marker, or a magnetic resonance moiety.

46. - 50. (Cancelled).

51. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 45, wherein said polypeptide is an HRGP fragment.

52. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 51, wherein said HRGP fragment comprises the central domain of HRGP.

53. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 51, wherein said HRGP fragment comprises at least one tandem repeat of the pentapeptide [H/P]-[H/P]PHG (SEQ ID NO:1).

54. – 55. (Cancelled).

56. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 45, wherein said polypeptide is at least 40 amino acids in length.

57. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 45, wherein said detectable marker is selected from the group consisting of fluorescein isothiocyanate, rhodamine, and luciferin.

58. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 45, wherein said enzymatic marker is selected from the group consisting of alkaline phosphatase, beta-galactosidase, and horseradish peroxidase.

59. (Previously presented) The substantially pure histidine-rich glycoprotein polypeptide of claim 45, wherein said detectable marker is a magnetic resonance moiety.

60. - 84. (Cancelled).